Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis
@article{Hirose2007AngiotensinIT, title={Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis}, author={A. Hirose and M. Ono and T. Saibara and Yasuko Nozaki and Kosei Masuda and Akemi Yoshioka and M. Takahashi and N. Akisawa and S. Iwasaki and J. Oben and S. Onishi}, journal={Hepatology}, year={2007}, volume={45} }
Nonalcoholic steatohepatitis (NASH) is now the most frequent cause of chronic liver impairment in developed countries and is a suggested causative factor in the development of cryptogenic cirrhosis and hepatocellular carcinoma. At present there is no effective and accepted therapy for NASH. The renin‐angiotensin system is involved in hepatic fibrosis through activation of hepatic stellate cells, major fibrogenic cells in the liver. Hepatic stellate cells are activated by liver injury to express… CONTINUE READING
Topics from this paper
201 Citations
Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis
- Medicine
- Journal of Gastroenterology
- 2012
- 29
Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis
- Medicine
- 2013
- 5
Third‐generation inhibitor for the renin–angiotensin system: Can it strongly protect against progression of hepatic fibrosis in non‐alcoholic steatohepatitis?
- Medicine
- Hepatology research : the official journal of the Japan Society of Hepatology
- 2013
Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C.
- Biology, Medicine
- American journal of physiology. Gastrointestinal and liver physiology
- 2009
- 90
- PDF
Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis
- Chemistry, Medicine
- Front. Pharmacol.
- 2018
- 6
- Highly Influenced
- PDF
The role of angiotensin II in nonalcoholic steatohepatitis
- Biology, Medicine
- Molecular and Cellular Endocrinology
- 2013
- 46
Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
- Medicine
- BMC Research Notes
- 2009
- 54
- Highly Influenced
Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis
- Chemistry, Medicine
- International journal of molecular sciences
- 2020
- PDF
Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
- Biology, Medicine
- International journal of molecular medicine
- 2012
- 31
- PDF
Salvianolic Acid B Attenuates Rat Hepatic Fibrosis via Downregulating Angiotensin II Signaling
- Medicine
- Evidence-based complementary and alternative medicine : eCAM
- 2012
- 50
- PDF
References
SHOWING 1-10 OF 38 REFERENCES
Angiotensin‐II type 1 receptor interaction is a major regulator for liver fibrosis development in rats
- Biology, Medicine
- Hepatology
- 2001
- 361
Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis.
- Biology, Medicine
- Gastroenterology
- 2001
- 270
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis
- Medicine
- Hepatology
- 2004
- 410
Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis.
- Biology, Medicine
- Journal of hepatology
- 2003
- 209
Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice.
- Biology, Medicine
- Journal of hepatology
- 2005
- 111
Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice
- Biology, Medicine
- Gut
- 2006
- 328
Antifibrotic effects of a tissue inhibitor of metalloproteinase‐1 antibody on established liver fibrosis in rats
- Biology, Medicine
- Hepatology
- 2004
- 173
COX‐2 induction in mice with experimental nutritional steatohepatitis: Role as pro‐inflammatory mediator
- Biology, Medicine
- Hepatology
- 2006
- 134